Standard BioTools Inc. cash flow to debt ratio of -241.18% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Standard BioTools Inc.'s free cash flow has increased -45.55% from $-151.81M last year to $-82.65M, signaling increasing performance

Standard BioTools Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Standard BioTools Inc.'s debt has decreased relative to shareholder equity from 0.07 last year to 0.05 today, signaling strengthened financials

Standard BioTools Inc. has negative EBITDA, making leverage ratio unreliable

Standard BioTools Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Standard BioTools Inc.'s profit margin has decreased (36.99%) in the last year from -79.62% to -109.08%, signaling decreasing performance

Standard BioTools Inc.'s short-term assets of $454.26M exceed its short-term liabilities of $108.31M

Standard BioTools Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Standard BioTools Inc.'s return on equity of -20.80%, is lower than 15.00%, indicating bad performance

Standard BioTools Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Standard BioTools Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Standard BioTools Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Standard BioTools Inc. has negative free cash flow, indicating cash burn

Standard BioTools Inc.'s yearly earnings has increased -46.07% since last year from $-138.88M to $-74.90M, signaling increasing performance

Standard BioTools Inc.'s yearly revenue has decreased -51.08% since last year from $174.43M to $85.33M, signaling decreasing performance

ROIC -7.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Standard BioTools Inc.'s 3-year revenue CAGR of -4.49% is negative, indicating declining revenue over the past 3 years

Standard BioTools Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Standard BioTools Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Standard BioTools Inc. has insufficient data to evaluate this check.

Standard BioTools Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Standard BioTools Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Standard BioTools Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Standard BioTools Inc. is overvalued relative to its fair value price of -1.51 based on Earnings Fair Value model

Standard BioTools Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Standard BioTools Inc. has a price-to-book ratio of 0.58x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Standard BioTools Inc. has a price-to-sales ratio of 3.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue